Antibe Therapeutics (ATBPF) 0.1560 $ATBPF Antibe

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antibe Therapeutics (ATBPF) 0.1560 $ATBPF

Antibe Therapeutics' Lead Drug Shows Promising Effects in Alveolar Bone Loss Study
Business Wire - Thu Oct 08, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV: ATE, OTCQX: ATBPF) is pleased to announce promising results from an independent bone loss study. A study directed by Dr. Marcelo Muscara at the University of Sao Paulo in Brazil provides compelling evidence that ATB-346, Antibe's lead drug candidate for treating chronic inflammatory conditions such as osteoarthritis, has a superior safety profile as compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs) in periodontal disease. NSAIDs, such as naproxen (Aleve), have well characterized adverse effects on bone growth. In the rat study performed by Dr. Muscara's team, induction of periodontitis, an inflammation of the gums, was associated with a marked loss of alveolar bone, which is the thickened ridge of bone that contains the tooth sockets. When the rats were treated with ATB-346 for a week, there was a substantial improvement in the preservation of alveolar bone, while naproxen treatment made the bone loss worse. These results open up potential uses of Antibe's drug candidates in the fields of regenerative medicine, orthopaedic and craniomaxillofacial surgery, where the adverse effects of NSAIDs on bone growth are an increasing concern.
ATE.VN: 0.170 (-0.010)

IIROC Trade Resumption - Antibe Therapeutics Inc.
Newsfile Corp - Tue Oct 06, 10:29AM CDT
Trading resumes in:

Antibe Therapeutics Announces Strategic Transactions
Business Wire - Tue Oct 06, 10:15AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has entered into agreements to complete strategic transactions that mark the transition of the Company from a development-focused biotechnology company to a diversified healthcare company with both development and commercial-stage assets across a broad range of markets.
ATE.VN: 0.170 (-0.010)

IIROC Trade Halt - Antibe Therapeutics Inc.
Newsfile Corp - Tue Oct 06, 7:04AM CDT
The following issues have been halted by IIROC:

Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 11.07 (+0.83), ARQL: 2.04 (+0.05), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), ATNM: 2.29 (+0.10), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), ARRY: 5.09 (+0.13)

Antibe Announces Completion of Phase I Studies of ATB-346 and an Update on Its Validation Studies
Business Wire - Mon Aug 10, 6:00AM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that the report on their Phase I studies of ATB-346, its lead drug, has been finalized. This milestone permits Antibe to proceed, when appropriate, with filing of applications to appropriate regulators for Phase II studies of ATB-346.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Reports Year-End Financial and Operating Results
Business Wire - Tue Jul 28, 6:45PM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2015. The Corporation's audited 2015 financial statements and MD&A are available on SEDAR.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces Addition of Aspirin Derivative to Its Product Pipeline and Provides an Update on Validation Studies
Business Wire - Mon Jul 20, 12:30PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE) is pleased to announce the addition to its product pipeline of ATB-340, a hydrogen sulfide-releasing derivative of aspirin.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock Options
Business Wire - Mon Jul 13, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE) today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013.
ATE.VN: 0.170 (-0.010)

Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 15.19 (+0.27), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), LLY: 86.14 (+2.37), NKTR: 11.34 (+0.56), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), POZN: 6.29 (+0.10), REGN: 503.92 (+12.71)

Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 3.64 (+0.17), TRVN: 10.13 (+0.26), KMPH: 18.83 (-0.18), MRK: 50.95 (-0.07), PCRX: 42.18 (+1.68), NKTR: 11.34 (+0.56)

Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews
Business Wire - Tue May 05, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE) announced today the following:
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces Additional Validation Data on ATB-346
Business Wire - Fri Apr 17, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE) announced today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,250,000
Business Wire - Thu Apr 09, 11:08PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE) closed the second and final closing of its previously announced non-brokered private placement of units, raising gross proceeds of $464,000 (the "Offering" . Under the terms of the Offering, 4,640,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until April 9, 2018.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Raises $786,000 in First Tranche of Non-Brokered Private Placement
Business Wire - Wed Apr 01, 9:15PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE) closed the first tranche of a non-brokered private placement of units, raising gross proceeds of $786,000 (the "Offering" . Under the terms of the offering, 7,860,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until April 1, 2018.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Provides an Update on Its Data Review and Corporate Strategy
Business Wire - Wed Mar 11, 7:21AM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF) announced today that it has completed the process of collecting and reviewing its Phase I data, further to its January 16, 2015 press release. As a result, Antibe has resumed the development of ATB-346.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces No Material Change
Business Wire - Wed Feb 04, 6:45PM CST
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF), wishes to confirm that its management is not aware of any corporate development or undisclosed material change to the Company or its operations that would account for the recent increase in market activity. Antibe continues to collect and assess data from its recently suspended Phase I clinical trial and will report back to the scientific community and the market with further details on its data review and corporate strategy as appropriate.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Suspends Its Phase I Clinical Trial Due to Safety Concerns
Business Wire - Fri Jan 16, 6:45AM CST
Antibe Therapeutics Inc. (TSXV:ATE; OTCQX:ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to Its Clinical Advisory Board
Business Wire - Thu Dec 18, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE; OTCQX:ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Canada.
ATE.VN: 0.170 (-0.010)

Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant
Business Wire - Tue Dec 16, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. ("Stonegate" based in Dallas, Texas. Under the terms of the agreement Stonegate will receive a monthly fee of $4,000 for a minimum of 6 months and will be granted 24,000 options. Such options will vest quarterly starting on the date of the grant, will be exercisable at a price of $0.52, and will expire October 31, 2017.
ATE.VN: 0.170 (-0.010)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 37

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 64

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 85

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 23

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 160

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 49

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 348

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

Flow Beverage Welcomes José Bautista as Advisor and Announces Fundraising Progress

Updated Category News Views 336

Flow Beverage Corp. Welcomes José Bautista as Strategic Advisor Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) has recently made a significant move by bringing on board José Bautista as a Strategic Advisor. This addition is seen as a promising enhancement to the company's team, aligning with its dedication to excellence and innovation in the beverage sector. Background of...

Continue Reading
Milan Laser Hair Removal Marks a Significant 400 Clinic Milestone

Updated Category News Views 207

Milan Laser Hair Removal Reaches 400 Clinics Nationwide The leading provider in laser hair removal achieves a remarkable milestone with nationwide expansion efforts. Milan Laser Hair Removal, the hallmark of laser hair removal in the nation, proudly celebrates the grand opening of its 400th clinic, symbolizing a major advancement in its rapid expansion across the country....

Continue Reading
Global Vertical Roller Mill Market Expands to USD 1.04 Billion

Updated Category News Views 215

Understanding the Global Vertical Roller Mill Market The Vertical Roller Mill (VRM) market is anticipated to experience significant growth in the coming years. Currently valued at approximately USD 608.5 million in 2024, projections indicate that it will reach USD 1,041.2 million by 2033, achieving a compound annual growth rate (CAGR) of 6.1%. This increase is largely due...

Continue Reading
Pulsar Helium Provides Insights on Progress at Topaz Project

Updated Category News Views 313

Pulsar Helium Develops Well-Testing Strategy at Topaz Project Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF), a leading helium development company, has recently provided valuable updates regarding its well-testing activities at the Topaz project, located in Minnesota. This momentous phase in the project holistically aims to assess helium extraction capabilities...

Continue Reading
Trade Disclosures: Treatt plc's Key Operations Analyzed

Updated Category News Views 178

Understanding Recent Trade Disclosures by Treatt plc Treatt plc, a company known for its expertise in manufacturing and distributing essential oils and flavouring agents, operates in a competitive sector where trade disclosures play a crucial role in maintaining transparency and building investor trust. As we delve into the recent disclosures made by Treatt plc, we'll...

Continue Reading